Virology

Develop machine-learning methods for early prediction of primary sclerosing cholangitis using clinical and national registry data. The project in the Nouairi research environment explores prediction in people with inflammatory bowel disease, with attention to calibration, validation and interpretable models. It is a research-training scholarship for eligible university students at Karolinska Institutet or a collaborating university. The source does not advertise an amount. Apply by 7 October 2026.

Funding for clinical trials and prospective or retrospective cohort studies, of either large or small scale, addressing important gaps in knowledge and producing evidence relevant to health outcomes, practice or policy. New applicants must submit minimum data by 5:00 pm ACT local time on 2026-10-07; this earlier mandatory milestone is the listing deadline. Complete applications close at 5:00 pm ACT local time on 2026-11-04. Apply through the eligible administering organisation using Sapphire. Full guidelines require GrantConnect login. Trial or cohort research for up to five years; excludes infrastructure costs and ongoing NHMRC support. Twelve-month milestone reporting is required. The published AUD 75 million is a total call budget, not an individual award.

The Healthy Brain Hub is seeking a Research Fellow to contribute to improving access to cognitive assessment through digital brain health approaches. Based within the School of Psychological Sciences and Turner Institute for Brain and Mental Health, the position will support study coordination, data collection and management, data analysis and evaluation of a digital brain health assessment platform across clinical settings. The role will also contribute to research protocols, ethics applications, funding activities and research outputs. The position will contribute to the scientific program through the analysis and interpretation of research data, preparation of manuscripts and conference presentations, and the development of research questions and ideas. It will also support the research environment through collaboration with colleagues and the supervision and mentoring of research assistants and students. The role provides an opportunity to apply advanced statistical methods, including mixed effects, survival, growth curve and prediction models, to research in neuropsychology, epidemiology, neurodegenerative disease and cognitive disorders. We are seeking someone with a doctoral qualification, or near completion of a doctoral qualification, in Psychology, Neuroepidemiology, Neuroscience, Neurology or a related discipline, together with demonstrated analytical and manuscript preparation skills and a record of refereed research publications. Knowledge of neuropsychology and epidemiological methods, advanced statistical analysis using programs such as R or SAS, and strong planning, organisational, communication and problem-solving skills are also important for this role. Join the Healthy Brain Hub and contribute to research that is helping advance accessible approaches to cognitive assessment and brain health. Job No.: 697564 Location: Clayton campus Employment Type: Full-time Duration: 12-months fixed-term appointment Remuneration: $86,195 - $116,981 pa Level A (plus 17% employer superannuation)

ESCAIDE brings together infectious-disease epidemiology, public-health practice and research. Its programme connects outbreak investigation, surveillance, genomic evidence, modelling and One Health approaches with prevention and health-security decisions. Plenaries examine distributed global public-health leadership and cooperation, the scientific infrastructure behind EU health security, communicating risk when trust is contested, integrated respiratory-infection surveillance, and modelling for public-health decisions. Contributed sessions cover respiratory and food- and water-borne diseases, antimicrobial resistance, surveillance and quantitative methods. Named plenary participants include Shingai Machingaidze (Coalition for Epidemic Preparedness Innovations / International Pandemic Preparedness Secretariat), Gianfranco Spiteri (ECDC), Helen Brown (Safinea, Ireland) and Magdalena Rosińska (National Public Health Institute, Poland). Their sessions consider evidence sharing and equity, capacity gaps, epidemic intelligence and analytical tools for coordinated responses. The conference runs 18–20 November 2026. Programme times are CET (Europe/Stockholm): the opening ceremony is 09:00 on 18 November; the first plenary is 09:30–10:30 and the EU health-security plenary 17:15–18:30 that day. The published programme is provisional and session details may change. Online participation is free, with unlimited general registration open through the conference days. Physical places are at capacity; on-site registration is limited to issued access codes or the waiting list. This listing offers online attendance through the official registration platform.

https://doi.org/10.1016/j.immuni.2022.10.005

Gunnveig Grødeland discusses competing explanations of the origins of COVID-19 and the evidence available at the episode's publication. Conversation in Norwegian.

After more than 4 million deaths worldwide, the ongoing vaccination to conquer the COVID-19 disease is now competing with the emergence of increasingly contagious mutations, repeatedly supplanting earlier strains. Following the near-absence of historical examples of the long-time evolution of infectious diseases under similar circumstances, models are crucial to exemplify possible scenarios. Accordingly, in the present work we systematically generalize the popular susceptible-infected-recovered model to account for mutations leading to repeatedly occurring new strains, which we coarse grain based on tools from statistical mechanics to derive a model predicting the most likely outcomes. The model predicts that mutations can induce a super exponential growth of infection numbers at early times, which self-amplify to giant infection waves which are caused by a positive feedback loop between infection numbers and mutations and lead to a simultaneous infection of the majority of the population. At later stages -- if vaccination progresses too slowly -- mutations can interrupt an ongoing decrease of infection numbers and can cause infection revivals which occur as single waves or even as whole wave trains featuring alternative periods of decreasing and increasing infection numbers. Our results might be useful for discussions regarding the importance of a release of vaccine-patents to reduce the risk of mutation-induced infection revivals but also to coordinate the release of measures following a downwards trend of infection numbers.